Norovirus cases are significantly increasing in the US and Canada. Moderna is developing an mRNA-based vaccine, currently in Phase 3 clinical trials, with the potential to be the first approved ...

Goldman Sachs downgraded the vaccine maker to Neutral from Buy and slashed its stock-price target to $51 from $99 Wednesday.

leading to severe symptoms and, in some cases, hospitalization,” said Stéphane Bancel, CEO of Moderna, in a statement last fall. “By advancing our investigational norovirus vaccine into a ...